HIGHLIGHTS
- who: Anna Fregnani and collaborators from the Hematology and Clinical Immunology Branch, Department of Medicine, University of Padova, Padova, Italy have published the article: CK1/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma, in the Journal: Cancers 2022, 14, 4173. of /2022/
- what: The authors investigated the role of CK1α in the osteoblastogenic potential of mesenchymal stromal cells (MSCs) and its involvement in MM-MSC cross-talk.
SUMMARY
Multiple myeloma (MM) is an incurable hematological malignancy of terminally differentiated plasma cells (PCs) which accounts for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.